Ratna Bhavaraju‐Sanka

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Regional variation of Guillain-Barré syndrome

Alex Y. Doets, Christine Verboon, Bianca van den Berg et al. · Brain · 2018 · 330 citations · Full text

Medicine, Internal Medicine, Neurology +16

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

<scp>Multi‐disciplinary</scp> collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with <scp>post‐acute</scp> sequelae of <scp>SARS‐CoV</scp>‐2 infection (<scp>PASC</scp>)

Svetlana Blitshteyn, Jonathan Whiteson, Benjamin Abramoff et al. · PM&R · 2022 · 77 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +12

Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study

Linda W.G. Luijten, Sonja E. Leonhard, Annemiek A. van der Eijk et al. · Brain · 2021 · 74 citations · Full text

Medicine, Infectious Diseases, Neurology +13